Core Viewpoint - 康诺亚-B's stock price increased by over 4% following the announcement of its drug 康悦达® being included in the National Basic Medical Insurance Drug List for 2025, effective from January 1, 2026 [1] Company Summary - 康诺亚-B's stock rose 4.23% to HKD 61.6 with a trading volume of HKD 1.3244 million [1] - The company announced that its self-developed Class 1 new drug 康悦达® (司普奇拜单抗 injection) has been included in the National Basic Medical Insurance Drug List [1] - 康悦达® is the first domestically developed and approved IL-4Rα humanized monoclonal antibody in China, targeting the dual blockade of IL-4/IL-13 signaling pathways to precisely inhibit the progression of type 2 inflammatory diseases [1] Drug Indications - 康悦达® has received approval for three indications: 1. Moderate to severe atopic dermatitis in adults inadequately controlled by topical medications 2. Chronic rhinosinusitis with nasal polyps inadequately controlled by corticosteroids and/or surgery 3. Moderate to severe seasonal allergic rhinitis in adults inadequately controlled by intranasal corticosteroids combined with antihistamines [1] - All three indications have been included in the updated National Basic Medical Insurance Drug List [1]
港股异动 | 康诺亚-B(02162)高开逾4% 司普奇拜单抗注射液纳入国家基本医疗保险药品目录